- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.04. | Unlock the Future of Patient Recruitment: Learnings from 15 Years of Innovation | ||
| 22.04. | Sanofi/Regeneron's Dupixent granted FDA approval for chronic spontaneous urticaria | ||
| 22.04. | GSK's Blenrep combinations approved by MHRA to treat multiple myeloma | ||
| 22.04. | FDA approves pre-filled syringe version of argenx's immune disorder drug Vyvgart | ||
| 22.04. | Coach Tolstoy: The surprising coaching lesson from Russian literature | ||
| 17.04. | GSK's five-in-one meningococcal vaccine recommended by CDC advisory committee | ||
| 17.04. | LEO Pharma and the Parker Institute join forces to advance dermatology research | ||
| 17.04. | FDA grants interchangeable designation to Celltrion's Humira biosimilar Yuflyma | ||
| 17.04. | The impact of multiple sclerosis on ageing patients | ||
| 16.04. | Shared decision-making in oncology - turning principles into practice | ||
| 16.04. | Biogen/Eisai's Alzheimer's disease drug Leqembi granted EC approval | ||
| 16.04. | Merck and Cyprumed enter oral peptide partnership worth over $493m | ||
| 16.04. | Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m | ||
| 16.04. | Reducing disparities in healthcare through shared decision-making | ||
| 15.04. | NHS programme to give melanoma patients fast-track access to skin cancer vaccine | ||
| 15.04. | J&J's subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma | ||
| 15.04. | Amgen shares positive phase 3 results for Imdelltra in small cell lung cancer | ||
| 15.04. | Point.1: Your first point in people-centred precision marketing | ||
| 14.04. | AstraZeneca's Truqap recommended by NICE to treat advanced breast cancer | ||
| 14.04. | BMS receives FDA approval for immunotherapy combination in liver cancer | ||
| 14.04. | Roche's Columvi granted EC approval to treat diffuse large B-cell lymphoma | ||
| 14.04. | How HCPs and patients are partnering to transform care | ||
| 11.04. | Novartis to invest $23bn into US-based infrastructure over next five years | ||
| 11.04. | Johnson & Johnson's subcutaneous Rybrevant granted EC approval to treat NSCLC | ||
| 11.04. | Bayer's Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .